Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting

Rhea-AI Summary

Vigil Neuroscience (Nasdaq: VIGL) announced two upcoming electronic poster presentations for the 2022 American Academy of Neurology Annual Meeting, detailing findings on adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The presentations focus on the lack of genotype-phenotype correlations and survival analysis of ALSP patients. VGL101, Vigil's leading monoclonal antibody, targets TREM2, crucial for microglial function, aiming to address the unmet need of treating ALSP, a rare neurological disease caused by CSF1R gene mutations, affecting approximately 10,000 individuals in the US.

News Market Reaction – VIGL

-8.60%

1 alert

-8.60% News Effect

On the day this news was published, VIGL declined 8.60%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced two poster presentations at the 2022 American Academy of Neurology (AAN) Annual Meeting. All posters will be presented electronically.

“Our presentations at this year’s AAN Annual Meeting highlight the lack of major genotype-phenotype correlations and the rapidly progressive nature of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) through a survival analysis. We hope these presentations help to improve the overall understanding of ALSP, our lead indication for VGL101, our investigational fully human monoclonal antibody TREM2 agonist,” said Spyros Papapetropoulos, MD, PhD, Chief Medical Officer of Vigil Neuroscience. “The Vigil team remains focused on enabling the development of safe and effective therapies for this devastating disease caused by genetic mutations affecting microglia function, for which there are currently no regulatory-approved therapies.”

Details of the poster presentations are as follows:

Title: “Survival analysis of patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): data from a systematic literature review of published case studies”
Session: P5 Neuroepidemiology 2, Poster 002 - Neighborhood 5
Date and time: Sunday, April 3, 2022 from 2:45 PM - 3:45 PM EST

Title: “Genotype-phenotype correlations in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)”
Session: P11 - Aging and Dementia: Non-Alzheimer's Dementia: Genetics and Neuroimaging 1, Poster 002 - Neighborhood 3
Date and time: Tuesday, April 5, 2022 from 2:45 PM - 3:45 PM EST

About VGL101
VGL101, Vigil’s lead product candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2), which is responsible for maintaining microglial cell function. TREM2 deficiency is believed to be a driver of certain neurodegenerative diseases. VGL101 is in development for the treatment of rare microgliopathies, such as adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), as well as other neurodegenerative diseases for which TREM2 and/or microglia deficiency is believed to be a key driver of disease pathway.

About ALSP
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare, inherited, autosomal dominant neurological disease with high penetrance. It is caused by a mutation to the CSF1R gene and affects an estimated 10,000 people in the US, with similar prevalence in Europe and Japan. The disease generally presents itself in adults in the forties, is diagnosed through genetic testing and established clinical/radiologic criteria and is characterized by cognitive dysfunction, neuropsychiatric symptoms, and motor impairment. These symptoms typically exhibit rapid progression with a life expectancy of approximately six to seven years on average after diagnosis, causing significant patient and caregiver burden. There are currently no approved therapies for the treatment of ALSP, underlining the high unmet need in this rare indication.

About Vigil Neuroscience
Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families.

FAQ

What is VGL101 and its significance related to Vigil Neuroscience?

VGL101 is Vigil Neuroscience's lead product candidate, a fully human monoclonal antibody designed to target TREM2, which helps maintain microglial function, crucial for treating neurodegenerative diseases.

What were the key findings presented by Vigil Neuroscience at the 2022 AAN Annual Meeting?

Vigil presented findings on the lack of genotype-phenotype correlations and survival analysis for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), improving understanding of the disease.

When and where will Vigil Neuroscience's AAN presentations take place?

The presentations will occur electronically at the AAN Annual Meeting on April 3, 2022, and April 5, 2022.

What is adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)?

ALSP is a rare inherited neurological disease caused by CSF1R gene mutations, affecting cognition and motor skills, with about 10,000 cases in the US.

Why is there a need for therapies like VGL101 for ALSP?

There are currently no approved therapies for ALSP, which has significant patient and caregiver burdens, highlighting the urgent need for effective treatments.